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Lymphatic mapping and sentinel node biopsy are widely
used to stage and manage patients with intermediate
and thicker primary cutaneous melanoma. Likelihood of
sentinel node metastases can be estimated from patients’
demography and primary tumor characteristics, but is
precisely determined only by microscopic evaluation of
excised node(s). Molecular/Genetic techniques, such as
RT-PCR, Gene Expression Microarray, detection of
metastasis-associated gene signatures and gene sequen-
cing are likely to increase precision in future. Recent
10 year results of Multicenter Selective Lymphadenect-
omy Trial 1 (MSLT1) [1] confirm that biopsy-based
management prolongs disease free survival for all node-
positive patients (P=0.01-0.03) and significantly increases
10 year distant disease-free survival (P=0.006) and mela-
noma-specific survival (P=0.02) for node-positive
patients with intermediate thickness primaries. The trial
also confirmed very clearly that the presence or absence
of sentinel node metastases is best determined by close
pathological evaluation of sections from nodal tissues,
stained conventionally and by immunohistochemistry
(S-100 protein, Mart-1, HMB-45). Patients with sentinel
node metastases have a significantly unfavorable out-
come that correlates with the amount and disposition of
nodal tumor as assessed by microscopy, immunohisto-
chemistry and morphometry [2]. Here again precision
will be increased by the parallel application of molecular
and genetic tests. The accuracy of appropriate patient
assignment to early surgical management will be drama-
tically increased by the addition of molecular testing,
more precisely identifying the patients most likely to
respond to standard and evolving therapies
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